NMN vs NR: Which NAD+ Precursor Actually Works?

Both NMN and NR flood supplement shelves with promises of restored energy, reversed aging, and enhanced cellular repair. Both raise NAD+ levels. Both cost more than most supplements in your stack. But they are not the same compound, and the differences matter more than most reviews admit.

This is the comparison guide that cuts through the positioning: what the biochemistry actually shows, what the clinical trials found, and how to decide which—if either—belongs in your protocol.

Why NAD+ Matters (The Short Version)

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in over 500 enzymatic reactions. It sits at the center of mitochondrial energy production, DNA repair, and sirtuin activation—the same sirtuins that respond to caloric restriction and fasting.

The problem: NAD+ declines with age. A 2012 analysis in Cell found that NAD+ levels in aged mice were roughly half those in young mice. Human data is consistent—by age 60, plasma NAD+ can be 40–60% lower than in young adults.

Why it drops: increased NAD+ consumption by DNA-repair enzymes (PARPs) under oxidative stress, reduced activity of biosynthesis enzymes, and declining precursor availability. Supplementing a direct precursor bypasses the slow endogenous synthesis pathway and can rapidly restore circulating NAD+.

Both NMN and NR are that shortcut—but they use slightly different entry points into the same biosynthetic pathway.

The Biochemistry: Different Entry Points

Nicotinamide Riboside (NR)

NR is a form of vitamin B3. It enters cells directly via nucleoside transporters (NRK1 and NRK2 transporters), then gets phosphorylated to NMN by NR kinase, and converted to NAD+. It was identified as an NAD+ precursor in a landmark 2004 Cell paper by Bieganowski and Brenner.

Molecular weight: 255 g/mol. It is orally bioavailable and stable in supplement form.

Nicotinamide Mononucleotide (NMN)

NMN is one step closer to NAD+ in the salvage pathway. For years, a debate existed about whether NMN could enter cells directly or required dephosphorylation to NR first. A 2019 paper by Grozio et al. in Nature Metabolism identified Slc12a8—a dedicated NMN transporter in the gut. This shifted the view: NMN can be absorbed intact and enter cells without converting to NR first.

Molecular weight: 334 g/mol. More complex to synthesize, which historically made it more expensive.

The Pathway Difference

Tryptophan → Nicotinamide → Nicotinamide Riboside (NR) → NMN → NAD+
                                         ↑
                              Both supplements enter here

NR enters at the NR step and gets phosphorylated to NMN before becoming NAD+. NMN enters at the NMN step. In practice, once absorbed, both converge rapidly on the same endpoint.

Clinical Evidence: What Human Trials Actually Show

NR Clinical Trials

Trammell et al. (2016, Nature Communications) — First human trial. 12 healthy adults took 100mg, 300mg, or 1000mg NR. Dose-dependent increases in blood NAD+: the 1000mg dose roughly doubled circulating NAD+ levels. No significant adverse effects.

Dellinger et al. (2017) — 120 adults over 60 years old. 1000mg NR for 6 weeks increased blood NAD+ by 142% vs placebo. Muscle NAD+ increased 45%. No effect on blood pressure, body composition, or glucose in this timeframe.

Martens et al. (2018, Nature Communications) — 30 middle-aged/older adults. NR supplementation elevated NAD+ metabolites and reduced a marker of aortic stiffness in a subgroup analysis. First hint of a vascular benefit.

Conze et al. (2019) — Safety and pharmacokinetics in healthy adults. 100mg to 1000mg doses well tolerated. Confirmed dose-dependent NAD+ elevation without meaningful adverse events.

NMN Clinical Trials

Yoshino et al. (2021, Science) — Arguably the most significant NMN human trial. 25 postmenopausal women with prediabetes or overweight. 250mg NMN daily for 10 weeks. Key finding: NMN increased skeletal muscle insulin sensitivity and improved insulin signaling pathway activity (specifically increased expression of genes involved in muscle remodeling). No systemic effect on body weight, blood pressure, or lipids. This was the first human trial showing NMN affects metabolic tissue function, not just NAD+ levels.

Liao et al. (2021, GeroScience) — 66 older adults (65–80 years). 250mg NMN daily for 12 weeks. Significant improvements in walking speed and grip strength vs placebo. Biomarkers of inflammation (IL-6, TNF-α) trended down. First trial showing functional physical outcomes.

Kim et al. (2022) — Healthy adults. 500mg NMN vs placebo. Blood NAD+ increased by roughly 38%. Lower dose than many trials, but still statistically significant elevation.

Yi et al. (2023) — Amateur runners, 300mg NMN for 6 weeks. Improved aerobic capacity (VO2 at ventilatory threshold) vs placebo. A focused athletic performance trial.

How the Evidence Stacks Up

Both raise NAD+. The functional outcomes—what changing that NAD+ level actually does in the body—are more studied in NMN trials to date, though this is partly because NMN trials are more recent and study designs have evolved.

Bioavailability: Does the Slc12a8 Transporter Change Everything?

The 2019 Grozio paper was treated as a watershed moment for NMN advocates: if NMN has its own dedicated intestinal transporter, it doesn’t need to convert to NR to be absorbed. The implication: higher concentrations can reach tissues intact and more quickly.

This is plausible, but the clinical significance remains contested. Critics of the Grozio paper note the data was primarily murine (mouse) intestinal cells, not confirmed in human intestinal tissue. A 2020 paper by Schmidt and Brenner argued the transporter data didn’t definitively prove NMN entered circulation intact at relevant doses.

The practical answer: both NR and NMN demonstrably raise blood NAD+ in humans. Whether NMN’s supposed direct cellular entry creates a clinically meaningful difference over NR is still an open question. No well-designed head-to-head trial has directly compared the two at equivalent doses in the same population.

Sublingual NMN: A Real Advantage?

A newer development in NMN formulation is sublingual delivery—dissolving a powder or tablet under the tongue to bypass gut processing entirely. ProHealth and other companies now offer sublingual NMN.

Bharat Bhatt et al. (2023, GeroScience) tested sublingual NMN directly against oral NMN. Key findings: sublingual delivery produced plasma NMN peaks approximately 40% higher than oral, and the elevation appeared faster (within minutes rather than the 1–2 hour oral absorption window).

Whether peak plasma NMN correlates with better tissue outcomes is still unclear. But if absorption is your concern, sublingual formulations have mechanistic support.

Dose and Protocol

NR Dosing (from clinical evidence)

• Minimum effective dose: 300mg/day (shows NAD+ elevation)
• Standard research dose: 500–1000mg/day
• Timing: Morning, with or without food—absorption appears food-independent
• Splitting doses: Some protocols split 500mg AM / 500mg PM to maintain sustained levels. Not well-studied, but theoretically reasonable

NMN Dosing (from clinical evidence)

• Minimum effective dose: 250mg/day (Yoshino and Liao trials used 250mg)
• Standard research dose: 250–500mg/day
• Higher doses: 750mg–1g/day are used in some protocols; David Sinclair and Andrew Huberman have both discussed 1g/day. No clear human trial supports superiority of 1g over 500mg
• Timing: Morning with first meal is common; Yoshino trial used morning dosing
• Sublingual: If using sublingual NMN, standard protocols suggest 100–250mg

With Resveratrol?

David Sinclair famously takes NMN with resveratrol, citing sirtuin synergy. The theory: resveratrol activates sirtuins, NMN provides the NAD+ fuel they need. The evidence for this specific combination in humans is thin. Resveratrol has poor oral bioavailability unless formulated with fat (micronized or liposomal). See our deep-dive on resveratrol when published. There’s no harm in combining them, but don’t treat the synergy as proven.

Safety and Side Effects

Both compounds have strong safety profiles in trials running up to 12 weeks. No serious adverse events have been reported in published human trials.

NR: Occasional reports of flushing (less than standard niacin/B3), nausea, or mild GI upset at doses above 1g/day. These are uncommon and generally mild.

NMN: Similarly clean profile. At very high doses (uncommon in trials), some GI sensitivity. One case report of elevated uric acid with high-dose NMN use—relevant if you have gout or elevated uric acid.

Long-term safety: Neither compound has long-term human safety data beyond 12 weeks. Given the mechanisms (sirtuin activation, PARP activation, DNA repair), theoretical concerns about interactions with cancer biology exist but have not materialized in short-term trials. Individuals with active cancer should discuss with their oncologist.

Drug interactions: Both are metabolized via NAD+ pathways. No confirmed interactions with common medications, but possible theoretical interactions with niacin (additive) or medications that affect NAD+ metabolism.

Price and Value

Prices have converged significantly as NMN manufacturing scaled up. The early premium for NMN over NR has largely disappeared. ChromaDex (NR) and Ames group-affiliated NMN brands remain the most studied formulations.

The Practical Decision

Choose NR if: - You want the longer track record of clinical research (NR was studied in humans first) - You’re focused on cardiovascular or systemic NAD+ elevation as the primary endpoint - You prefer a compound where the absorption mechanism is fully understood

Choose NMN if: - Muscle insulin sensitivity or physical performance is your primary goal (Yoshino and Liao trials specifically) - You want to use the sublingual form for faster absorption - You’re following a protocol from Huberman or Sinclair, who both use NMN

Choose either if: - Your primary goal is simply raising blood NAD+ levels—both do this comparably well

Consider skipping both if: - You’re under 35 with no metabolic dysfunction—the NAD+ decline that drives benefit is most pronounced after 40–50 - Your lifestyle NAD+ depressors (alcohol, sleep deprivation, chronic stress, sedentary) are unaddressed—supplementing around these factors has less impact than fixing them

What the Competitors Miss

Most NMN vs NR comparisons either (a) sell one of the compounds, (b) treat them as interchangeable, or (c) ignore the distinction between raising blood NAD+ and actually producing downstream functional outcomes.

The critical nuance: blood NAD+ elevation is a biomarker, not an outcome. Yoshino et al. specifically measured skeletal muscle insulin sensitivity, muscle gene expression, and metabolic function—not just plasma NAD+. If you’re evaluating these supplements by “how much does it raise my NAD+?”, you’re measuring the proxy, not the thing you actually care about.

The better question: what functional outcomes do you want, and which compound has trial evidence specifically for that outcome?

Internal Links

• NAD+ and NMN: The Longevity Supplement, Examined
• Taurine: The Longevity Amino Acid
• Rapamycin and the Longevity Frontier

Bottom Line

NMN and NR both work. Both raise NAD+. The functional clinical evidence—particularly for muscle metabolism and physical performance—skews toward NMN in more recent trials, though NR has the longer safety record. Head-to-head data doesn’t yet exist.

If you’re over 40, metabolically healthy but aging, and want to support mitochondrial function: 250–500mg NMN or 500mg NR daily, taken in the morning, is a reasonable protocol. Don’t expect dramatic acute effects—the benefits are long-horizon and difficult to feel. Track objective markers (metabolic panel, physical performance, body composition) rather than subjective energy if you want signal from the experiment.

The science is genuinely promising. Just not as settled as the marketing suggests.